Chargement en cours...
Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
The approved standard dose of pazopanib is 800 mg per day, but the appropriate dose of pazopanib to treat soft tissue sarcoma (STS) patients in real-world practice is controversial. Of 124 STS patients treated with pazopanib, we retrospectively analyzed the cases of STS patients who achieved progres...
Enregistré dans:
| Publié dans: | J Clin Med |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6352274/ https://ncbi.nlm.nih.gov/pubmed/30626115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8010060 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|